Based on safety and efficacy analysis, we provided evidence regarding the beneficial effect of palbociclib in ER‐positive and HER2‐negative breast cancer and the potential value of palbociclib in Rb‐positive germ cell tumors and Rb‐positive liposarcoma. This evidence concerns the gene ESR1 and liposarcoma.